在肥胖症治疗市场,诺和诺德和礼来公司的减肥药物一直占据主导地位。但周一公布的一项新数据或将改变这一格局。
新兴生物制药公司Viking Therapeutics公布了其新型减肥药VK2735的临床试验数据。该数据显示,该药物采用口服和注射两种给药方式,在减重效果和使用便利性方面较现有产品具有优势。
根据Viking Therapeutics公布的数据,VK2735口服剂型在28天试验中能使受试者平均减重8.2%。虽然这一效果略逊于诺和诺德的Wegovy和礼来的Zepbound,但这两种药物都只有注射剂型。相比之下,口服VK2735或将为不愿注射的患者提供新的选择。另一方面,VK2735注射剂可实现每月一次给药,而Wegovy和Zepbound需要每周注射一次。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.